UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   Form 10-QSB

--------------------------------------------------------------------------------


(Mark one)
    XX          QUARTERLY  REPORT  UNDER  SECTION  13 OR 15(d) OF THE SECURITIES
----------      EXCHANGE ACT OF 1934

                      For the quarterly period ended March 31, 2000

                TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE  ACT
----------      OF 1934

                      For the transition period from ____________ to ___________

--------------------------------------------------------------------------------


                         Commission File Number: 2-90519

                           ProHealth Laboratories, Inc
        (Exact name of small business issuer as specified in its charter)

          Nevada                                              59-2262718
--------------------------                           ---------------------------
 (State of incorporation)                              (IRS Employer ID Number)

                  211 West Wall Street, Midland, TX 70701-4556
                    (Address of principal executive offices)

                                 (915) 682-1761
                           (Issuer's telephone number)

                          DCC Acquisition Corporation
             1201 Chester Industrial Parkway, Avon, Ohio 44011-1081
             ------------------------------------------------------
                     (Former name, former address and former
                   fiscal year, if changed since last report)


--------------------------------------------------------------------------------

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YES    NO X
                                                             ---   ---

State the number of shares outstanding of each of the issuer's classes of common
equity as of the latest practicable date: April 30, 2001: 152,247
                                          -----------------------

Transitional Small Business Disclosure Format (check one): YES     NO X
                                                               ---   ---



                          ProHealth Laboratories, Inc.

                Form 10-QSB for the Quarter ended March 31, 2000

                                Table of Contents


                                                                            Page
                                                                            ----
Part I - Financial Information

  Item 1   Financial Statements                                               3

  Item 2   Management's Discussion and Analysis or Plan of Operation         10


Part II - Other Information

  Item 1   Legal Proceedings                                                 11

  Item 2   Changes in Securities                                             11

  Item 3   Defaults Upon Senior Securities                                   11

  Item 4   Submission of Matters to a Vote of Security Holders               12

  Item 5   Other Information                                                 12

  Item 6   Exhibits and Reports on Form 8-K                                  12


Signatures                                                                   12






                                                                               2




S. W. HATFIELD, CPA
certified public accountants

Member:    American Institute of Certified Public Accountants
               SEC Practice Section
               Information Technology Section
           Texas Society of Certified Public Accountants

Item 1 - Part 1 - Financial Statements


                           Accountant's Review Report
                           --------------------------


Board of Directors and Shareholders
ProHealth Laboratories, Inc.

We have reviewed the accompanying balance sheets of ProHealth Laboratories, Inc.
(a  Nevada  corporation)  as of March  31,  2000  and 1999 and the  accompanying
statements of operations and  comprehensive  income and cash flows for the three
months ended March 31, 2000 and 1999. These financial statements are prepared in
accordance  with  the  instructions  for Form  10-QSB,  as  issued  by the U. S.
Securities  and  Exchange  Commission,  and are the sole  responsibility  of the
Company's management.

We conducted our review in accordance with standards established by the American
Institute  of  Certified  Public  Accountants.  A review  of  interim  financial
information consists principally of applying analytical  procedures to financial
data and making  inquiries of persons  responsible  for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with  generally  accepted  auditing  standards,  the  objective  of which is the
expression on an opinion  regarding the financial  statements  taken as a whole.
Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material  modifications that should
be made to the  accompanying  financial  statements for them to be in conformity
with generally accepted accounting principles.

The  accompanying  financial  statements  have been  prepared  assuming that the
Company  will  continue  as a  going  concern.  As  discussed  in  Note A to the
financial statements, the Company has no viable operations or significant assets
and is dependent upon  significant  shareholders to provide  sufficient  working
capital to maintain the integrity of the corporate entity.  These  circumstances
create  substantial  doubt  about the  Company's  ability to continue as a going
concern and are discussed in Note A. The financial statements do not contain any
adjustments that might result from the outcome of these uncertainties.


                                                       S. W. HATFIELD, CPA
Dallas, Texas
April 23, 2001




                      Use our past to assist your future sm

P. O. Box 820395                               9002 Green Oaks Circle, 2nd Floor
Dallas, Texas  75382-0395                               Dallas, Texas 75243-7212
214-342-9635 (voice)                                          (fax) 214-342-9601
800-244-0639                                                      SWHCPA@aol.com
                                        3





                          ProHealth Laboratories, Inc.
                                 Balance Sheets
                             March 31, 2000 and 1999

                                   (Unaudited)

                                                               2000         1999
                                                             ---------    ---------
                                                                    
                                     Assets
                                     ------
Assets
   Cash on hand and in bank                                  $    --      $    --
                                                             ---------    ---------

Total Assets                                                 $    --      $    --
                                                             =========    =========


                      Liabilities and Shareholders' Equity
                      ------------------------------------

 Liabilities
   Accounts payable - trade                                  $   1,185    $   2,390
                                                             ---------    ---------

     Total liabilities                                           1,185        2,390
                                                             ---------    ---------

Commitments and contingencies

Shareholders' Equity
   Common stock - $0.0001 par value
     100,000,000 shares authorized
     145,640 shares issued and
     outstanding,  respectively                                     15           15
   Additional paid-in capital                                  805,782      801,160
   Accumulated deficit                                        (806,982)    (803,565)
                                                             ---------    ---------

   Total Shareholders' Equity (Deficit)                         (1,185)      (2,390)
                                                             ---------    ---------

   Total Liabilities and Shareholders' Equity                $    --      $    --
                                                             =========    =========




The  financial  information  presented  herein has been  prepared by  management
without audit by independent  certified  public  accountants.  See  Accountant's
Review Report.  The  accompanying  notes are an integral part of these financial
statements.
                                                                               4



                          ProHealth Laboratories, Inc.
                Statements of Operations and Comprehensive Income
                   Three months ended March 31, 2000 and 1999

                                   (Unaudited)

                                         Three months   Three months
                                             ended          ended
                                           March 31,      March 31,
                                             2000           1999
                                         ------------   ------------

Revenues                                   $    --        $    --
                                           ---------      ---------

Expenses
   General and administrative expenses           222            159
                                           ---------      ---------

Net Loss                                        (222)          (159)

Other Comprehensive Income                      --             --
                                           ---------      ---------

Comprehensive Income                       $    (222)     $    (159)
                                           ---------      ---------

Loss per weighted-average share
   of common stock outstanding,
   computed on Net Loss - basic
   and fully diluted                             nil            nil
                                           =========      =========

Weighted-average number of shares
   of common stock outstanding               145,640        145,640
                                           =========      =========


The  financial  information  presented  herein has been  prepared by  management
without audit by independent  certified  public  accountants.  See  Accountant's
Review Report.  The  accompanying  notes are an integral part of these financial
statements.
                                                                               5





                          ProHealth Laboratories, Inc.
                            Statements of Cash Flows
                   Three months ended March 31, 2000 and 1999

                                   (Unaudited)

                                                            Three months Three months
                                                                ended        ended
                                                              March 31,    March 31,
                                                                2000         1999
                                                             ----------   ----------
                                                                    
Cash Flows from Operating Activities
   Net Loss                                                  $     (222)  $     (159)
   Adjustments to reconcile net income to net cash
      provided by operating activities
         Increase in Accounts payable - trade                       222          159
                                                             ----------   ----------

Net cash used in operating activities                              --           --
                                                             ----------   ----------


Cash Flows from Investing Activities                               --           --
                                                             ----------   ----------


Cash Flows from Financing Activities                               --           --
                                                             ----------   ----------

Increase (Decrease) in Cash and Cash Equivalents                   --           --

Cash and cash equivalents at beginning of period                   --           --
                                                             ----------   ----------

Cash and cash equivalents at end of period                   $     --     $     --
                                                             ==========   ==========

Supplemental Disclosures of Interest and Income Taxes Paid
   Interest paid during the period                           $     --     $     --
                                                             ==========   ==========
   Income taxes paid (refunded)                              $     --     $     --
                                                             ==========   ==========



The  financial  information  presented  herein has been  prepared by  management
without audit by independent  certified  public  accountants.  See  Accountant's
Review Report.  The  accompanying  notes are an integral part of these financial
statements.
                                                                               6



                          ProHealth Laboratories, Inc.
                        (formerly DCC Acquisition Corp.)

                          Notes to Financial Statements


Note A - Organization and Description of Business

ProHealth  Laboratories,  Inc. (Company) was originally  incorporated on January
26, 1983 under the laws of the State of Florida as Datalink  Systems,  Inc.  for
the  purpose  of  marketing  electronic  information  processing  systems to the
medical and  healthcare  industries.  As of December 31,  1986,  the Company had
closed this business operation.

The Company changed its corporate name to Datalink Capital  Corporation in April
1987 and to Midland Capital Resources,  Inc. in April 1991.  Subsequent thereto,
the  Company  forfeited  its  corporate  charter in the State of Florida  due to
non-payment  of various  taxes and fees. In July 1997,  the Company's  corporate
charter was reactivated with the State of Florida and changed its corporate name
to Datalink Capital Corporation, effective September 24, 1997.

On December  29,  1998,  the Company  changed  its State of  Incorporation  from
Florida  to  Nevada  by  means  of  a  merger  with  and  into  DCC  Acquisition
Corporation, a Nevada corporation formed solely for the purpose of effecting the
reincorporation.  The  Articles  of  Incorporation  and  Bylaws  of  the  Nevada
corporation  are the  Articles  of  Incorporation  and  Bylaws of the  surviving
corporation. Such Articles of Incorporation did not change the capital structure
of the Company and  effectively  changed the corporate  name to DCC  Acquisition
Corporation.

In November 1999, in anticipation  of a business  combination  transaction,  the
Company  experienced  a change in control.  As a result of the change in control
and the anticipated  business combination  transaction,  the Company changed its
corporate name to ProHealth  Laboratories,  Inc.  Subsequently,  the anticipated
business combination transaction did not occur.

The  Company  has  had  no  operations,   assets  or  liabilities   since  1989.
Accordingly,  the  Company  is  dependent  upon  management  and/or  significant
shareholders to provide  sufficient working capital to preserve the integrity of
the  corporate  entity  at  this  time.  It is  the  intent  of  management  and
significant  shareholders to provide  sufficient  working  capital  necessary to
support and preserve the  integrity of the corporate  entity.  Through March 31,
2000, various Company  shareholders have advanced  approximately  $7,500 through
direct payments for operating expenses on behalf of the Company.

The Company follows the accrual basis of accounting in accordance with generally
accepted accounting principles and has a year-end of December 31.

During interim periods, the Company follows the accounting policies set forth in
its annual  audited  financial  statements  filed with the U. S.  Securities and
Exchange  Commission  on its  Annual  Report on Form  10-KSB  for the year ended
December 31, 1999.  The  information  presented  within these interim  financial
statements  may not  include all  disclosures  required  by  generally  accepted
accounting  principles  and the  users of  financial  information  provided  for
interim periods should refer to the annual  financial  information and footnotes
when reviewing the interim financial results presented herein.

In the opinion of management,  the accompanying  interim  financial  statements,
prepared in  accordance  with the U. S.  Securities  and  Exchange  Commission's
instructions   for  Form  10-QSB,   are   unaudited  and  contain  all  material
adjustments,  consisting  only of  normal  recurring  adjustments  necessary  to
present fairly the financial condition,  results of operations and cash flows of
the Company for the respective  interim  periods  presented.  The current period
results of operations are not necessarily indicative of results which ultimately
will be reported for the full fiscal year ending December 30, 2000.


                                                                               7



                          ProHealth Laboratories, Inc.
                        (formerly DCC Acquisition Corp.)

                    Notes to Financial Statements - Continued


Note A - Organization and Description of Business - Continued

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
the  reported  amounts of revenues  and expenses  during the  reporting  period.
Actual results could differ from those estimates.


Note B - Summary of Significant Accounting Policies

1. Cash and cash equivalents
   -------------------------

   For Statement of Cash Flows purposes,  the Company considers all cash on hand
   and in banks, including accounts in book overdraft positions, certificates of
   deposit and other  highly-liquid  investments with maturities of three months
   or less, when purchased, to be cash and cash equivalents.

2. Income Taxes
   ------------

   At March 31, 2000,  as a result of the November  1999 change in control,  the
   Company has a net  operating  loss  carryforward  for income tax  purposes of
   approximately  $3,200.  If this  carryforward is not fully utilized,  it will
   begin to expire in 2019.  As of March 31,  2000 and 1999,  respectively,  the
   deferred tax asset related to the Company's net operating  loss  carryforward
   is fully reserved.

3. Earnings (loss) per share
   -------------------------

   Basic earnings (loss) per share is computed by dividing the net income (loss)
   by the  weighted-average  number of shares of common  stock and common  stock
   equivalents  (primarily  outstanding  options  and  warrants).  Common  stock
   equivalents  represent  the  dilutive  effect of the assumed  exercise of the
   outstanding stock options and warrants,  using the treasury stock method. The
   calculation of fully diluted  earnings  (loss) per share assumes the dilutive
   effect of the  exercise of  outstanding  options  and  warrants at either the
   beginning  of the  respective  period  presented  or the  date  of  issuance,
   whichever is later. As of March 31, 2000 and 1999, respectively,  the Company
   had no warrants and/or options outstanding.


Note C - Fair Value of Financial Instruments

The carrying amount of cash,  accounts  receivable,  accounts  payable and notes
payable, as applicable,  approximates fair value due to the short term nature of
these items  and/or the current  interest  rates  payable in relation to current
market conditions.



                                                                               8



                          ProHealth Laboratories, Inc.
                        (formerly DCC Acquisition Corp.)

                    Notes to Financial Statements - Continued


Note D - Income Taxes

The components of income tax (benefit) expense  for the three months ended March
31, 2000 and 1999, respectively, are as follows:
                                      March 31,   March 31,
                                        2000        1999
                                      ---------   ---------
         Federal:
            Current                   $       -   $       -
            Deferred                          -           -
                                      ---------   ---------
                                              -           -
                                      ---------   ---------
         State:
            Current                           -           -
            Deferred                          -           -
                                      ---------   ---------
                                              -           -
                                      ---------   ---------

            Total                     $       -   $       -
                                      =========   =========

As of March 31, 2000,  as a result of the November  1999 change in control,  the
Company has a net operating loss carryforward of approximately  $3,200 to offset
future taxable income.  Subject to current  regulations,  this carryforward will
begin to expire in 2019. The amount and  availability  of the net operating loss
carryforwards  may be subject to limitations  set forth by the Internal  Revenue
Code. Factors such as the number of shares ultimately issued within a three year
look-back  period;  whether  there is a deemed  more than 50  percent  change in
control; the applicable long-term tax exempt bond rate; continuity of historical
business;  and  subsequent  income  of the  Company  all enter  into the  annual
computation of allowable annual utilization of the carryforwards.

The  Company's  income tax  expense for the years ended March 31, 2000 and 1999,
respectively, are as follows:

                                                       March 31,   March 31,
                                                         2000        1999
                                                       ---------   ---------
Statutory rate applied to loss before income taxes     $     (75)  $     (54)
Increase (decrease) in income taxes resulting from:
     State income taxes                                        -           -
     Other, including reserve for deferred tax asset          75          54
                                                       ---------   ---------

       Income tax expense                              $       -   $       -
                                                       =========   =========

Temporary  differences,  consisting primarily of statutory deferrals of expenses
for organizational costs and statutory  differences in the depreciable lives for
property and equipment, between the financial statement carrying amounts and tax
bases of assets and liabilities give rise to deferred tax assets and liabilities
as of March 31, 2000 and 1999, respectively:

                                                       March 31,   March 31,
                                                         2000        1999
                                                       ---------   ---------
       Deferred tax assets
         Net operating loss carryforwards              $   1,090   $       -
         Less valuation allowance                         (1,090)          -
                                                       ---------   ---------

       Net Deferred Tax Asset                          $       -   $       -
                                                       =========   =========


                                                                               9



                          ProHealth Laboratories, Inc.
                        (formerly DCC Acquisition Corp.)

                    Notes to Financial Statements - Continued


Note E - Common Stock Transactions

On October  22,  1999,  effective  November  1,  1999,  the  Company's  Board of
Directors approved and enacted a 1:10 reverse split of its Common Stock, $0.0001
par value,  with  fractional  shares rounded up to the nearest whole share.  The
accompanying financial statements reflect this action as of the first day of the
first period presented.





                (Remainder of this page left blank intentionally)








                                                                              10



Part I - Item 2

Management's  Discussion  and  Analysis of  Financial  Condition  and Results of
Operations

(1)    Caution Regarding Forward-Looking Information

This  quarterly   report  contains   certain   forward-looking   statements  and
information relating to the Company that are based on the beliefs of the Company
or management as well as assumptions made by and information currently available
to  the  Company  or  management.   When  used  in  this  document,   the  words
"anticipate,"   "believe,"   "estimate,"   "expect"  and  "intend"  and  similar
expressions,  as they relate to the Company or its  management,  are intended to
identify forward-looking statements. Such statements reflect the current view of
the  Company   regarding  future  events  and  are  subject  to  certain  risks,
uncertainties  and  assumptions,  including the risks and  uncertainties  noted.
Should  one or more of  these  risks or  uncertainties  materialize,  or  should
underlying assumptions prove incorrect,  actual results may vary materially from
those  described  herein  as  anticipated,   believed,  estimated,  expected  or
intended. In each instance,  forward-looking information should be considered in
light of the accompanying meaningful cautionary statements herein.

(2)    Results of Operations, Liquidity and Capital Resources

Discussion of Financial Condition
---------------------------------

As of the  date of  this  filing,  the  Company  has no  operations,  assets  or
liabilities.  Accordingly,  the  Company is  dependent  upon  management  and/or
significant  shareholders to provide  sufficient working capital to preserve the
integrity of the  corporate  entity at this time. It is the intent of management
and significant  shareholders to provide sufficient working capital necessary to
support and  preserve  the  integrity  of the  corporate  entity.  All  expenses
incurred  during the quarter  ended March 31, 2000 related to general  operating
costs necessary to maintain the corporate entity.

The  Company  will  remain  illiquid  until such time as a business  combination
transaction  occurs, if ever. No prediction of the future financial condition of
the Company can be made.

Plan of Business
----------------

General
-------

The  Company  intends to locate and  combine  with an  existing,  privately-held
company which is profitable  or, in  management's  view,  has growth  potential,
irrespective of the industry in which it is engaged.  However,  the Company does
not  intend  to  combine  with a  private  company  which may be deemed to be an
investment  company subject to the Investment Company Act of 1940. A combination
may be structured as a merger,  consolidation,  exchange of the Company's common
stock for stock or assets or any other form which  will  result in the  combined
enterprise's becoming a publicly-held corporation.

Pending  negotiation and consummation of a combination,  the Company anticipates
that it will have, aside from carrying on its search for a combination  partner,
no business  activities,  and, thus, will have no source of revenue.  Should the
Company incur any significant  liabilities prior to a combination with a private
company, it may not be able to satisfy such liabilities as are incurred.

If the Company's management pursues one or more combination opportunities beyond
the  preliminary  negotiations  stage and those  negotiations  are  subsequently
terminated,  it is  foreseeable  that such efforts  will  exhaust the  Company's
ability to continue to seek such combination opportunities before any successful
combination can be consummated.  In that event,  the Company's common stock will
become  worthless  and  holders of the  Company's  common  stock will  receive a
nominal distribution, if any, upon the Company's liquidation and dissolution.



                                                                              11



Combination Suitability Standards
---------------------------------

In its pursuit for a combination  partner,  the Company's  management intends to
consider only  combination  candidates  which are profitable or, in management's
view, have growth potential.  The Company's management does not intend to pursue
any  combination  proposal  beyond the  preliminary  negotiation  stage with any
combination  candidate which does not furnish the Company with audited financial
statements  for at least its most  recent  fiscal year and  unaudited  financial
statements for interim periods  subsequent to the date of such audited financial
statements, or is in a position to provide such financial statements in a timely
manner.  The Company will, if necessary  funds are available,  engage  attorneys
and/or accountants in its efforts to investigate a combination  candidate and to
consummate a business  combination.  The Company may require  payment of fees by
such combination  candidate to fund the investigation of such candidate.  In the
event such a combination candidate is engaged in a high technology business, the
Company may also obtain  reports from  independent  organizations  of recognized
standing  covering the technology  being developed and/or used by the candidate.
The  Company's  limited  financial  resources may make the  acquisition  of such
reports  difficult  or even  impossible  to obtain  and,  thus,  there can be no
assurance  that the Company  will have  sufficient  funds to obtain such reports
when considering combination proposals or candidates.  To the extent the Company
is  unable to  obtain  the  advice or  reports  from  experts,  the risks of any
combined enterprise's being unsuccessful will be enhanced.  Furthermore,  to the
knowledge of the Company's officers and directors, neither the candidate nor any
of  its  directors,   executive  officers,  principal  shareholders  or  general
partners:

         (1)      will not have been convicted of securities  fraud, mail fraud,
                  tax  fraud,  embezzlement,  bribery,  or  a  similar  criminal
                  offense  involving  misappropriation  or theft of funds, or be
                  the subject of a pending investigation or indictment involving
                  any of those offenses;

         (2)      will  not  have  been  subject  to a  temporary  or  permanent
                  injunction   or   restraining   order  arising  from  unlawful
                  transactions  in securities,  whether as issuer,  underwriter,
                  broker,  dealer, or investment advisor,  may be the subject of
                  any pending  investigation or a defendant in a pending lawsuit
                  arising   from  or  based   upon   allegations   of   unlawful
                  transactions in securities; or

         (3)      will  not  have  been a  defendant  in a  civil  action  which
                  resulted  in a  final  judgement  against  it or him  awarding
                  damages or rescission  based upon unlawful  practices or sales
                  of securities.

The Company's  officers and directors will make these  determinations  by asking
pertinent  questions of the  management of prospective  combination  candidates.
Such persons will also ask pertinent  questions of others who may be involved in
the combination proceedings.  However, the officers and directors of the Company
will not generally take other steps to verify independently information obtained
in this manner which is favorable.  Unless  something  comes to their  attention
which  puts  them on  notice  of a  possible  disqualification  which  is  being
concealed  from them,  such persons will rely on  information  received from the
management of the prospective  combination  candidate and from others who may be
involved in the combination proceedings.


Part II - Other Information

Item 1 - Legal Proceedings

       None

Item 2 - Changes in Securities

       None

Item 3 - Defaults on Senior Securities

       None

                                                                              12



Item 4 - Submission of Matters to a Vote of Security Holders

       The  Company  has held no regularly scheduled, called or special meetings
       of shareholders during the reporting period.

Item 5 - Other Information

       None

Item 6 - Exhibits and Reports on Form 8-K

       Exhibits - None
       Reports on Form 8-K - None

--------------------------------------------------------------------------------

                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

                                                    ProHealth Laboratories, Inc.


April   30  , 2001                                    /s/ Glenn A. Little.
      ------                                        ----------------------------
                                                                 Glenn A. Little
                                                          President and Director



                                                                              13